Purpose Several cases have been reported in which central nervous system (CNS) metastases of non-small cell lung cancer (NSCLC) resistant to geWtinib were improved by erlotinib. However, there has been no study in which cerebrospinal Xuid (CSF) concentrations of geWtinib and erlotinib are directly compared. Thus, we aimed to compare them. Methods We examined 15 Japanese patients with NSCLC and CNS metastases with epidermal growth factor receptor gene mutations who received CSF examinations during epidermal growth factor receptor-tyrosine kinase inhibitors treatment (250 mg daily geWtinib or 150 mg daily erlotinib). Plasma and CSF concentrations were determined using high-performance liquid chromatography with tandem mass spectrometry. Results The concentration and penetration rate of geWtinib (mean § standard deviation) in the CSF were 3.7 § 1.9 ng/mL (8.2 § 4.3 nM) and 1.13 § 0.36 %, respectively. The concentration and penetration rate of erlotinib in the CSF were 28.7 § 16.8 ng/mL (66.9 § 39.0 nM) and 2.77 § 0.45 %, respectively. The CSF concentration and penetration rate of erlotinib were signiWcantly higher than those of geWtinib (P = 0.0008 and <0.0001, respectively). The CNS response rates of patients with erlotinib treatment were preferentially (but not signiWcantly) higher than those with geWtinib treatment. (1/3 vs. 4/7, respectively). Leptomeningeal metastases in one patient, which were refractory to geWtinib, dramatically responded to erlotinib. Conclusions This study suggested that higher CSF concentration could be achieved with erlotinib and that erlotinib could be more eVective for the treatment for CNS metastases, especially leptomeningeal metastases, than geWtinib.
Introduction
Somatic activating mutations of the epidermal growth factor receptor (EGFR) gene (EGFR mutations) were Wrst discovered in 2004 [1, 2] . Patients with non-small cell lung cancer (NSCLC) with EGFR mutations generally respond to EGFR-tyrosine kinase inhibitors (EGFR-TKIs; for example, geWtinib and erlotinib) and achieve long-term progression-free survival (PFS) [1, 2] . Nevertheless, the majority of these patients experience eventual disease progression, despite an initial dramatic response to treatment. The CNS is a common site of recurrence, and this is thought to be due to the penetration of the agents into the CNS [3, 4] . A report described refractory CNS metastases of NSCLC that were improved by high-dose geWtinib treatment [5] . Several cases in which intermittent, high-dose erlotinib improved CNS metastases that were resistant to continuous, normal-dose erlotinib has also been reported [6] [7] [8] [9] . These observations suggest the hypothesis that high cerebrospinal Xuid (CSF) concentrations can be achieved by the high-dose administration of EGFR-TKIs. In addition, there have been several cases in which CNS metastases resistant to geWtinib were improved by erlotinib, suggesting that higher CSF concentrations can be achieved with erlotinib than with geWtinib [10] . Although some reports have shown the CSF concentration of each agent [5, [11] [12] [13] [14] , the CSF concentrations of geWtinib and erlotinib have never been directly compared. Thus, in the present study, we investigated the plasma and CSF concentrations of geWtinib and erlotinib in patients with NSCLC and CNS metastases with EGFR mutations.
Patients and methods

Patients
We examined 15 Japanese patients with NSCLC and CNS metastases with EGFR mutations who received CSF examinations during EGFR-TKI treatment (250 mg daily geWtinib or 150 mg daily erlotinib) between April 2010 and March 2012 at Kyoto University Hospital. Two of the 15 patients received geWtinib and erlotinib treatment; therefore, we analyzed 17 plasma and 17 CSF samples from 15 patients. Before the collection of samples and analyses, we obtained written informed consent from all patients. This study was approved by the Ethics Committee of Kyoto University Graduate School and Faculty of Medicine.
Sample analysis
Blood and CSF samples were obtained just before the administration of EGFR-TKIs when their plasma concentration had achieved a steady state, that is, after day 8. Plasma and CSF concentrations of geWtinib and erlotinib were determined using high-performance liquid chromatography with tandem mass spectrometry, as previously reported [15] [16] [17] [18] .
EGFR mutational analysis
Formalin-Wxed, paraYn-embedded tissue blocks or cytological samples were used for DNA analysis. No CNS lesions were used for DNA analysis. We adopted the peptic nucleic acid-locked nucleic acid (PNA-LNA) polymerase chain reaction (PCR) clamp method, according to the previously described protocol [19] . BrieXy, PNA clamp primers inhibit the ampliWcation of the wildtype sequence, and LNA probes are used to speciWcally detect mutant sequences in the presence of wild-type sequences. The synergistic eVect of these primers causes the speciWc PCR ampliWcation of mutant sequences. SpeciWc PNA-LNA probe sets to each mutation were developed to cover >95 % of EGFR mutations previously reported in Japan [20] .
Response evaluation
Except for case 7 and 11, the response of CNS disease was assessed using magnetic resonance imaging (MRI) and the Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 [21] . However, RECIST deWnes leptomeningeal metastases as "nontarget" lesions, and a clear but incomplete response is designated as a "noncomplete response/ nonprogressive disease" rather than either a partial response or stable disease. Thus, the patient with clearly improved leptomeningeal disease (Fig. 1a, b ) was designated as a partial responder.
Statistical analysis
Continuous variables were analyzed using the t test, and the results were expressed as the mean § standard deviation. Dichotomous variables were analyzed using Fisher's exact test. All analyses, performed by using JMP 8 software (SAS Institute, Cary, NC, USA), were two-tailed, and P values less than 0.05 were considered statistically signiWcant. 
Results
The clinical characteristics of all patients (n = 15) are summarized in Table 1 . Six patients received CSF examinations during geWtinib treatment (cases 1-6), 7 patients during erlotinib treatment (cases 7-13), and 2 patients during both treatments (cases 14 and 15). In addition to cases 14 and 15, case 10 received geWtinib treatment before erlotinib treatment, but he did not receive a CSF examination during geWtinib treatment. Cases 1 and 14 did not have CNS metastases before the initiation of geWtinib, but they had subsequent CNS metastases and received a CSF examination. Cases 7, 11, and 15 had leptomeningeal metastases as determined by CSF cytology.
The plasma and CSF concentrations of EGFR-TKIs are summarized in Table 2 . The CSF concentration and penetration rate of geWtinib were 3.7 § 1.9 ng/mL (8.2 § 4.3 nM) and 1.13 § 0.36 %, respectively. The CSF concentration and penetration rate of erlotinib were 28.7 § 16.8 ng/mL (66.9 § 39.0 nM) and 2.77 § 0.45 %, respectively. The CSF concentration and penetration rate of erlotinib were signiWcantly higher than those of geWtinib (t test, P = 0.0008 and <0.0001, respectively) (Fig. 2) .
By formal RECIST evaluation, the response rate of CNS disease was 38 % (3/8). However, case 15 achieved a clear radiographic response with erlotinib treatment (Fig. 1a, b) . Although case 7 could not receive the brain MRI, her symptoms, performance status (PS), and CSF cytology improved following the initiation of erlotinib treatment. Although case 11 also could not receive the brain MRI, her symptoms, PS, and CSF cytology got worsened in spite of erlotinib treatment. Including these patients, there was no signiWcant diVerence between geWtinib and erlotinib (1/3 vs. 4/7, Fisher's exact test, P = 1.00).
The leptomeningeal metastases of case 15, which were refractory to geWtinib, dramatically responded to erlotinib (Fig. 1a, b) . The CSF concentration of geWtinib was 7.2 nM and that of erlotinib increased to 68.2 nM. His PS, which had deteriorated to 4 due to leptomeningeal metastases during geWtinib treatment, improved to 2 after the initiation of erlotinib treatment.
Discussion
This study demonstrated that the CSF concentration and penetration rate of erlotinib were signiWcantly higher than those of geWtinib. Although these results were similar to those of previous reports [5, [11] [12] [13] [14] , to the best of our knowledge, this is the Wrst report in which the CSF concentration and penetration rate of both agents were analyzed and directly compared. Patients with NSCLC who have EGFR mutations generally respond to EGFR-TKIs [1, 2] . Although systemic chemotherapy for CNS metastases has been thought to play a limited role because the brain is believed to be a pharmacologic sanctuary site [22] , several reports have documented the eVectiveness of EGFR-TKIs in the treatment for CNS metastases of NSCLC with EGFR mutations. Although these patients dramatically respond to the treatment, the majority of them eventually undergo disease progression. The CNS is a common site of recurrence, which is thought to be due to the poor penetration of the agents into the CNS [3, 4] . Therefore, considering the higher CSF concentration of erlotinib, patients may achieve longer PFS with erlotinib treatment than with geWtinib treatment. Indeed, one pooled analysis showed such results [23] .
GeWtinib and erlotinib are similar anilinoquinazoline compounds. Although it seems that erlotinib has a slightly broader spectrum of kinase inhibition than geWtinib [24] , they are essentially EGFR-speciWc TKIs. The most prominent diVerence between these two drugs is the dose setting. The approved daily dose of erlotinib (150 mg) is equal to the maximum tolerated dose (MTD) of erlotinib. In contrast, the daily dose of geWtinib was set at 250 mg, approximately one-third of the MTD of geWtinib [25] [26] [27] [28] . This diVerence seemed to have a great inXuence on our results. In addition, there seems to be diVerences in the penetration rates of geWtinib and erlotinib. A major protein constituent of the blood-brain barrier (BBB) is P-glycoprotein (P-gp), which pumps chemotherapy drugs and toxins out of the CNS [29, 30] . The penetration diVerences of geWtinib and erlotinib may be dependent on their aYnity for P-gp.
The CNS response rates of patients with erlotinib treatment were preferentially (but not signiWcantly) higher than those with geWtinib treatment. But this result is debatable because the number of patients examined was very small and there were several diVerences in their backgrounds. In fact, the CNS metastases of case 2 responded to geWtinib even though its CSF concentration was lower than its median inhibitory concentration [31] . Several studies have suggested that chemotherapeutic agents can reach parenchymal brain metastases [32, 33] . The observed contrast enhancement of parenchymal brain metastases on computed tomography and MRI also suggests that the BBB is at least partially disrupted in such patients [34] . In addition, a recent report demonstrated that [ 11 C]-erlotinib positron emission tomography showed accumulation in parenchymal brain metastases [35] . In contrast, leptomeningeal metastases can be distinguished from parenchymal brain metastases since they are associated with the spread of malignant cells throughout the subarachnoid space [36, 37] . Some cases have been reported in which leptomeningeal metastases refractory to geWtinib responded to erlotinib, as observed in case 15 [10] . In this case, an approximately 10 times higher CSF concentration of erlotinib (68.2 nM) was achieved than with geWtinib (7.2 nM). Therefore, erlotinib can be more eVective for leptomeningeal metastases than geWtinib due to its higher CSF concentration.
Patients with leptomeningeal metastases have a reduced PS and very poor prognosis [36, 37] . While most clinicians evaluate CSF cytology together with MRI and clinical examinations, underdiagnosis is a major problem [36, 37] . Therefore, even if a deWnite diagnosis is not made, considering the CSF concentration, erlotinib should be administered prior to geWtinib when patients are suspected of having leptomeningeal metastases.
In conclusion, the CSF concentration and penetration rate of erlotinib are higher than those of geWtinib, which supports the view that patients can achieve longer PFS with erlotinib treatment than with geWtinib and that erlotinib can be more eVective for the treatment for CNS metastases, especially leptomeningeal metastases, than geWtinib. However, it is debatable whether erlotinib is more eVective for parenchymal brain metastases than geWtinib. In order to conWrm these Wndings, large prospective studies should be performed. 
